Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

TransThera Biosciences

Request full access

Research and development of innovative drugs in oncology, cardiovascular, and inflammatory diseases

Nanjing City, ChinaFounded 2016Biotech & Life Sciences

About TransThera Biosciences

A clinical-stage biopharmaceutical company specializing in the development of small-molecule drugs to address unmet medical needs. The company's research and development efforts are concentrated on therapeutics for oncology, cardiovascular, and inflammatory diseases.

TransThera Biosciences operates in the biotechnology sector, focusing on advancing its pipeline of drug candidates through clinical trials. The company has received Investigational New Drug (IND) approval from the FDA for its drug candidate TT-00920, intended for the treatment of chronic heart failure. This milestone allows the company to initiate Phase 1 clinical trials to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug.

The company's business model involves strategic research and development collaborations, such as the one with Teijin Pharma, to advance its therapeutic programs. By focusing on areas with significant unmet medical needs, TransThera Biosciences aims to develop and commercialize novel treatments for a global market.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2025
Outcome tier
Unicorn$1–10B valuation tier

TransThera Biosciences in the Nanjing City ecosystem

Live from Dealroom

The TransThera Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

20 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • GP Capital

Series B and later19 investors entered at this stage

  • Ocean Pine Healthcare Fund
  • SDIC Venture Capital
  • Shenzhen Cornerstone Asset Management
  • Ennovation Ventures
  • Grand Yangtze Capital
  • China Merchants Capital
  • CITIC PE
  • China Structural Reform Fund
  • China Renaissance
  • GP Healthcare Capital
  • Sixty Degree Capital
  • Ruihua Holdings
  • Trinity Innovation Fund
  • Dunhang Capital
  • Guolian Financial Investment Qiyuan
  • Nanjing Jiangbei State-owned Assets
  • Ruitong Venture Capital
  • BOCG Investment
  • Guoxin Capital
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇨🇳 China81.8%
🇺🇸 United States18.2%
2 countries shown
Web traffic by country
200 monthly visits
across markets
🇩🇪 Germany100%
Top 1 markets shown

Patents

Estimated portfolio value
$78M

81 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about TransThera Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See TransThera Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.